212 related articles for article (PubMed ID: 29507805)
1. Serum mesothelin and other biomarkers: what have we learned in the last decade?
Cristaudo A; Bonotti A; Guglielmi G; Fallahi P; Foddis R
J Thorac Dis; 2018 Jan; 10(Suppl 2):S353-S359. PubMed ID: 29507805
[TBL] [Abstract][Full Text] [Related]
2. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
[TBL] [Abstract][Full Text] [Related]
3. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
Katz SI; Roshkovan L; Berger I; Friedberg JS; Alley EW; Simone CB; Haas AR; Cengel KA; Sterman DH; Albelda SM
Lung Cancer; 2021 Apr; 154():5-12. PubMed ID: 33561782
[TBL] [Abstract][Full Text] [Related]
6. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
8. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
9. Serum diagnostic markers for malignant pleural mesothelioma: a narrative review.
Wang JJ; Yan L
Transl Cancer Res; 2022 Dec; 11(12):4434-4440. PubMed ID: 36644178
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and prognosis-review of biomarkers for mesothelioma.
Sun HH; Vaynblat A; Pass HI
Ann Transl Med; 2017 Jun; 5(11):244. PubMed ID: 28706912
[TBL] [Abstract][Full Text] [Related]
11. Soluble markers for diagnosis of malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Bruno R; Foddis R
Biomark Med; 2011 Apr; 5(2):261-73. PubMed ID: 21473730
[TBL] [Abstract][Full Text] [Related]
12. Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network.
Pass HI; Alimi M; Carbone M; Yang H; Goparaju CM
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2524-2540. PubMed ID: 32699075
[TBL] [Abstract][Full Text] [Related]
13. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
[TBL] [Abstract][Full Text] [Related]
15. Soluble mesothelin-related protein in malignant pleural mesothelioma.
Azim HA; Gaafar R; Abdel Salam I; El-Guindy S; Elattar I; Ashmawy A; Khorshid O
J Egypt Natl Canc Inst; 2008 Sep; 20(3):224-9. PubMed ID: 20424652
[TBL] [Abstract][Full Text] [Related]
16. Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels.
Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Bruno R; Gemignani F; Landi S
Int J Biol Markers; 2011; 26(2):117-23. PubMed ID: 21574151
[TBL] [Abstract][Full Text] [Related]
17. Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma.
Fujimoto N; Gemba K; Asano M; Wada S; Ono K; Ozaki S; Kishimoto T
Exp Ther Med; 2010 Mar; 1(2):313-317. PubMed ID: 22993544
[TBL] [Abstract][Full Text] [Related]
18. Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.
Sorino C; Mondoni M; Marchetti G; Agati S; Inchingolo R; Mei F; Flamini S; Lococo F; Feller-Kopman D
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002620
[TBL] [Abstract][Full Text] [Related]
19. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
